Helena Neudorf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helena Neudorf has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Peter Little
School of Health and Exercise Sciences University of British Columbia Okanagan Kelowna British Columbia Canada
4 shared publications - Hashim Islam
University of British Columbia Okanagan
2 shared publications - Jeremy J. Walsh
McMaster University
2 shared publications Joel Singer
University of British Columbia, School of Population and Public Health , Vancouver, BC, Canada
2 shared publications- Kaja Falkenhain
Pennington Biomedical Research Center
2 shared publications Kenneth Madden
University of British Columbia, Department of Medicine, Centre of Aging SMART , Vancouver, BC , Canada
2 shared publications
Latest Publications
- Open Access
Insulin Prevents Fat Loss and Promotes Muscle Loss During Intermittent Fasting in Obesity
Elevated blood glucose, insulin, and insulin resistance are associated with obesity and type 2 diabetes (T2D). High blood insulin levels blunt lipolysis and promote lipogenesis, and thus weight gain. Intermittent fasting (IF) has emerged as a weight loss strategy that also lowers blood glucose and improves insulin resistance. However, some people with obesity, or T2D have less fat loss and more lean mass loss after IF. It is not known why some people lose more fat or muscle during IF. We hypothesized that features of obesity, such as high insulin and insulin action in adipocytes dictate less adipose loss and more muscle loss during IF. In humans, we found that people living with obesity and higher blood insulin lost more lean mass after a 48-hour fast. Chronic elevation of insulin in obese mice lowered adipose loss and promoted muscle loss after 10 weeks of 5:2 IF in obese mice, while concurrently lowering adipose tissue interferon regulatory factor 4 (IRF4) expression. Whole-body and adipocyte-specific deletion of Irf4 in mice phenocopied chronic hyperinsulinemia, resulting in less fat loss and greater muscle loss after 10 weeks of 5:2 IF, which occurred in mouse models of equal and reduced caloric intake during IF. Therefore, hyperinsulinemia and suppression of adipocyte IRF4 promote muscle loss over fat loss during IF. Significance Statement: It is not known why some people lose muscle during IF. In humans, we found that high blood insulin during obesity correlated with increased lean mass loss after one 48-hour fast. Mechanistically, we found that hyperinsulinemia and the insulin responsive factor IRF4 within adipocytes as regulators of adipose and muscle loss during chronic IF obese mice. Therefore, insulin status and regulation of adipocyte IRF4 may be important factors to consider before prescribing IF for weight loss as lower muscle mass is known to be detrimental to metabolic and overall health status.
Open AccessInsulin Prevents Fat Loss and Promotes Muscle Loss During Intermittent Fasting in Obesity
Elevated blood glucose, insulin, and insulin resistance are associated with obesity and type 2 diabetes (T2D). High blood insulin levels blunt lipolysis and promote lipogenesis, and thus weight gain. Intermittent fasting (IF) has emerged as a weight loss strategy that also lowers blood glucose and improves insulin resistance. However, some people with obesity, or T2D have less fat loss and more lean mass loss after IF. It is not known why some people lose more fat or muscle during IF. We hypothesized that features of obesity, such as high insulin and insulin action in adipocytes dictate less adipose loss and more muscle loss during IF. In humans, we found that people living with obesity and higher blood insulin lost more lean mass after a 48-hour fast. Chronic elevation of insulin in obese mice lowered adipose loss and promoted muscle loss after 10 weeks of 5:2 IF in obese mice, while concurrently lowering adipose tissue interferon regulatory factor 4 (IRF4) expression. Whole-body and adipocyte-specific deletion of Irf4 in mice phenocopied chronic hyperinsulinemia, resulting in less fat loss and greater muscle loss after 10 weeks of 5:2 IF, which occurred in mouse models of equal and reduced caloric intake during IF. Therefore, hyperinsulinemia and suppression of adipocyte IRF4 promote muscle loss over fat loss during IF. Significance Statement: It is not known why some people lose muscle during IF. In humans, we found that high blood insulin during obesity correlated with increased lean mass loss after one 48-hour fast. Mechanistically, we found that hyperinsulinemia and the insulin responsive factor IRF4 within adipocytes as regulators of adipose and muscle loss during chronic IF obese mice. Therefore, insulin status and regulation of adipocyte IRF4 may be important factors to consider before prescribing IF for weight loss as lower muscle mass is known to be detrimental to metabolic and overall health status.
- Open Access
- 1 February 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (2) , C541-C556
Effect of exogenous β-hydroxybutyrate on BDNF signaling, cognition, and amyloid precursor protein processing in humans with T2D and insulin-resistant rodents
Ketone supplementation does not alter circulating BDNF levels or cognition in humans with T2D. Acute and chronic ketone supplementation in C57BL/6J mice did not change BDNF protein content or improve recognition memory. Ketone supplementation in C57BL/6J mice positively modulated β-site amyloid precursor protein cleaving enzyme 1 (BACE1) activity, providing a potential future therapeutic strategy.
- 1 February 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (2) , C541-C556
Open AccessEffect of exogenous β-hydroxybutyrate on BDNF signaling, cognition, and amyloid precursor protein processing in humans with T2D and insulin-resistant rodents
Ketone supplementation does not alter circulating BDNF levels or cognition in humans with T2D. Acute and chronic ketone supplementation in C57BL/6J mice did not change BDNF protein content or improve recognition memory. Ketone supplementation in C57BL/6J mice positively modulated β-site amyloid precursor protein cleaving enzyme 1 (BACE1) activity, providing a potential future therapeutic strategy.
- 9 January 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 216 (1) , 89-103
Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes
Pre-clinical and cell culture evidence supports the role of the ketone beta-hydroxybutyrate (BHB) as an immunomodulatory molecule that may inhibit inflammatory signalling involved in several chronic diseases such as type 2 diabetes (T2D), but studies in humans are lacking. Therefore, we investigated the anti-inflammatory effect of BHB in humans across three clinical trials. To investigate if BHB suppressed pro-inflammatory cytokine secretion, we treated LPS-stimulated leukocytes from overnight-fasted adults at risk for T2D with BHB (Study 1). Next (Study 2), we investigated if exogenously raising BHB acutely in vivo by ketone monoester supplementation (KME) in adults with T2D would suppress pro-inflammatory plasma cytokines. In Study 3, we investigated the effect of BHB on inflammation via ex vivo treatment of LPS-stimulated leukocytes with BHB and in vivo thrice-daily pre-meal KME for 14 days in adults with T2D. Ex vivo treatment with BHB suppressed LPS-stimulated IL-1β, TNF-α, and IL-6 secretion and increased IL-1RA and IL-10 (Study 1). Plasma IL-10 increased by 90 min following ingestion of a single dose of KME in T2D, which corresponded to peak blood BHB (Study 2). Finally, 14 days of thrice-daily KME ingestion did not significantly alter plasma cytokines or leukocyte subsets including monocyte and T-cell polarization (Study 3). However, direct treatment of leukocytes with BHB modulated TNF-α, IL-1β, IFN-γ, and MCP-1 secretion in a time- and glucose-dependent manner (Study 3). Therefore, BHB appears to be anti-inflammatory in T2D, but this effect is transient and is modulated by the presence of disease, glycaemia, and exposure time.
- 9 January 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 216 (1) , 89-103
Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes
Pre-clinical and cell culture evidence supports the role of the ketone beta-hydroxybutyrate (BHB) as an immunomodulatory molecule that may inhibit inflammatory signalling involved in several chronic diseases such as type 2 diabetes (T2D), but studies in humans are lacking. Therefore, we investigated the anti-inflammatory effect of BHB in humans across three clinical trials. To investigate if BHB suppressed pro-inflammatory cytokine secretion, we treated LPS-stimulated leukocytes from overnight-fasted adults at risk for T2D with BHB (Study 1). Next (Study 2), we investigated if exogenously raising BHB acutely in vivo by ketone monoester supplementation (KME) in adults with T2D would suppress pro-inflammatory plasma cytokines. In Study 3, we investigated the effect of BHB on inflammation via ex vivo treatment of LPS-stimulated leukocytes with BHB and in vivo thrice-daily pre-meal KME for 14 days in adults with T2D. Ex vivo treatment with BHB suppressed LPS-stimulated IL-1β, TNF-α, and IL-6 secretion and increased IL-1RA and IL-10 (Study 1). Plasma IL-10 increased by 90 min following ingestion of a single dose of KME in T2D, which corresponded to peak blood BHB (Study 2). Finally, 14 days of thrice-daily KME ingestion did not significantly alter plasma cytokines or leukocyte subsets including monocyte and T-cell polarization (Study 3). However, direct treatment of leukocytes with BHB modulated TNF-α, IL-1β, IFN-γ, and MCP-1 secretion in a time- and glucose-dependent manner (Study 3). Therefore, BHB appears to be anti-inflammatory in T2D, but this effect is transient and is modulated by the presence of disease, glycaemia, and exposure time.
- 1 January 2024
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 326 (1) , E61-E72
The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials
Exogenous ketone supplements can acutely lower blood glucose, suggesting therapeutic potential in individuals with impaired glucose metabolism. However, the effect of exogenous ketones on glucose metabolism in adults with type 2 diabetes has not been investigated in a controlled setting. In adults with type 2 diabetes, ketone monoester ingestion did not lower blood glucose acutely in a fasted state and did not improve glycemic control across thrice daily premeal ingestion across 14 days.
- 1 January 2024
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 326 (1) , E61-E72
The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials
Exogenous ketone supplements can acutely lower blood glucose, suggesting therapeutic potential in individuals with impaired glucose metabolism. However, the effect of exogenous ketones on glucose metabolism in adults with type 2 diabetes has not been investigated in a controlled setting. In adults with type 2 diabetes, ketone monoester ingestion did not lower blood glucose acutely in a fasted state and did not improve glycemic control across thrice daily premeal ingestion across 14 days.
- 1 April 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (3) , 302-306.e4
A Low-Carbohydrate, High-Fat Ketogenic Diet Program Implemented by an Interdisciplinary Primary Care Team Improves Markers of Cardiometabolic Health in Adults With Type 2 Diabetes: A Retrospective Secondary Analysis
- 1 April 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (3) , 302-306.e4
A Low-Carbohydrate, High-Fat Ketogenic Diet Program Implemented by an Interdisciplinary Primary Care Team Improves Markers of Cardiometabolic Health in Adults With Type 2 Diabetes: A Retrospective Secondary Analysis